Literature DB >> 34993766

Interconnected high-dimensional landscapes of epithelial-mesenchymal plasticity and stemness in cancer.

Sarthak Sahoo1,2, Bazella Ashraf3, Atchuta Srinivas Duddu1, Adrian Biddle4, Mohit Kumar Jolly5.   

Abstract

Establishing macrometastases at distant organs is a highly challenging process for cancer cells, with extremely high attrition rates. A very small percentage of disseminated cells have the ability to dynamically adapt to their changing micro-environments through reversibly switching to another phenotype, aiding metastasis. Such plasticity can be exhibited along one or more axes-epithelial-mesenchymal plasticity (EMP) and cancer stem cells (CSCs) being the two most studied, and often tacitly assumed to be synonymous. Here, we review the emerging concepts related to EMP and CSCs across multiple cancers. Both processes are multi-dimensional in nature; for instance, EMP can be defined on morphological, molecular and functional changes, which may or may not be synchronized. Similarly, self-renewal, multi-lineage potential, and resistance to anoikis and/or therapy may not all occur simultaneously in CSCs. Thus, understanding the complexity in defining EMP and CSCs is essential if we are to understand their contribution to cancer metastasis. This will require a more comprehensive understanding of the non-linearity of these processes. These processes are dynamic, reversible, and semi-independent in nature; cells traverse the inter-connected high-dimensional EMP and CSC landscapes in diverse paths, each of which may exhibit a distinct EMP-CSC coupling. Our proposed model offers a potential unifying framework for elucidating the coupled decision-making along these dimensions and highlights a key set of open questions to be answered.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cancer stem cells; Epithelial–mesenchymal plasticity; Landscape; Metastasis; Phenotypic plasticity; Stemness

Mesh:

Year:  2022        PMID: 34993766     DOI: 10.1007/s10585-021-10139-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  94 in total

1.  MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination.

Authors:  Mingyang Lu; Mohit Kumar Jolly; Herbert Levine; José N Onuchic; Eshel Ben-Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-23       Impact factor: 11.205

2.  Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative.

Authors:  Adrian Biddle; Xiao Liang; Luke Gammon; Bilal Fazil; Lisa J Harper; Helena Emich; Daniela Elena Costea; Ian C Mackenzie
Journal:  Cancer Res       Date:  2011-06-17       Impact factor: 12.701

Review 3.  EMT Transition States during Tumor Progression and Metastasis.

Authors:  Ievgenia Pastushenko; Cédric Blanpain
Journal:  Trends Cell Biol       Date:  2018-12-26       Impact factor: 20.808

4.  Identification of the tumour transition states occurring during EMT.

Authors:  Ievgenia Pastushenko; Audrey Brisebarre; Alejandro Sifrim; Marco Fioramonti; Tatiana Revenco; Soufiane Boumahdi; Alexandra Van Keymeulen; Daniel Brown; Virginie Moers; Sophie Lemaire; Sarah De Clercq; Esmeralda Minguijón; Cédric Balsat; Youri Sokolow; Christine Dubois; Florian De Cock; Samuel Scozzaro; Federico Sopena; Angel Lanas; Nicky D'Haene; Isabelle Salmon; Jean-Christophe Marine; Thierry Voet; Panagiota A Sotiropoulou; Cédric Blanpain
Journal:  Nature       Date:  2018-04-18       Impact factor: 49.962

Review 5.  Cancer Stem Cells and Epithelial-to-Mesenchymal Transition in Cancer Metastasis.

Authors:  Toni Celià-Terrassa; Mohit Kumar Jolly
Journal:  Cold Spring Harb Perspect Med       Date:  2020-07-01       Impact factor: 5.159

6.  An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).

Authors:  R Y-J Huang; M K Wong; T Z Tan; K T Kuay; A H C Ng; V Y Chung; Y-S Chu; N Matsumura; H-C Lai; Y F Lee; W-J Sim; C Chai; E Pietschmann; S Mori; J J H Low; M Choolani; J P Thiery
Journal:  Cell Death Dis       Date:  2013-11-07       Impact factor: 8.469

Review 7.  Distinctive properties of metastasis-initiating cells.

Authors:  Toni Celià-Terrassa; Yibin Kang
Journal:  Genes Dev       Date:  2016-04-15       Impact factor: 11.361

Review 8.  EMT and MET: necessary or permissive for metastasis?

Authors:  Mohit Kumar Jolly; Kathryn E Ware; Shivee Gilja; Jason A Somarelli; Herbert Levine
Journal:  Mol Oncol       Date:  2017-06-12       Impact factor: 6.603

9.  Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states.

Authors:  Kamen P Simeonov; China N Byrns; Megan L Clark; Robert J Norgard; Beth Martin; Ben Z Stanger; Jay Shendure; Aaron McKenna; Christopher J Lengner
Journal:  Cancer Cell       Date:  2021-06-10       Impact factor: 31.743

10.  Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.

Authors:  Tuan Zea Tan; Qing Hao Miow; Yoshio Miki; Tetsuo Noda; Seiichi Mori; Ruby Yun-Ju Huang; Jean Paul Thiery
Journal:  EMBO Mol Med       Date:  2014-10       Impact factor: 12.137

View more
  3 in total

1.  Quantifying the Patterns of Metabolic Plasticity and Heterogeneity along the Epithelial-Hybrid-Mesenchymal Spectrum in Cancer.

Authors:  Srinath Muralidharan; Sarthak Sahoo; Aryamaan Saha; Sanjay Chandran; Sauma Suvra Majumdar; Susmita Mandal; Herbert Levine; Mohit Kumar Jolly
Journal:  Biomolecules       Date:  2022-02-12

2.  Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis.

Authors:  Maalavika Pillai; Gouri Rajaram; Pradipti Thakur; Nilay Agarwal; Srinath Muralidharan; Ankita Ray; Dev Barbhaya; Jason A Somarelli; Mohit Kumar Jolly
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

Review 3.  Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis.

Authors:  Goodwin G Jinesh; Andrew S Brohl
Journal:  Signal Transduct Target Ther       Date:  2022-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.